Navigation Links
US Patent Office Issues Patent for VG Life Sciences' Peptide for HIV Treatment
Date:10/31/2013

SANTA BARBARA, Calif., Oct. 31, 2013 /PRNewswire/ -- VG Life Sciences, Inc. is a publicly traded (VGLS) biotechnology company focused on developing treatments for patients suffering autoimmune and infectious diseases.

(Logo: http://photos.prnewswire.com/prnh/20131031/LA07859LOGO)

The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection. The VG1177 peptide prevents the survival of pro-inflammatory cells under conditions where inflammation is unwanted, thereby allowing the body's natural containment systems to provide protection from harm.

The hallmarks of chronic HIV infections are chronic inflammation and loss of CD4 T cells. Thus this patent may have important implications for treating inflammation associated with HIV infection and AIDS.

The patent will be issued to the University of Colorado (CU) and has been licensed exclusively to VG Life Sciences as a result of the invention filed by VG Life Sciences' Lead Scientist, Dr. M. Karen Newell Rogers, PhD, during her tenure at the University of Colorado Colorado Springs.  Dr. Newell Rogers is currently at Texas A&M University College of Medicine and Baylor Scott and White Health Care.

The patent abstract reads as follows:

"The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject."

John Tynan, VG Life Sciences' President and CEO said, "First, this is a great recognition of Dr. Newell Rogers' hard work and ground breaking research. Second, this reflects our commitment to expand and secure our IP portfolio."

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company working on discovering and developing drug therapies for infectious diseases, cancer and many autoimmune diseases. VGLS controls over 50 US and international patents and patents pending protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements

 This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences' drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact:

Alexandria Sumner, Director of Corporate Communications
VG Life Sciences, Inc.
Phone:  (805) 679-6763
Email:  asumner@vglifesciences.com


'/>"/>
SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
3. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
6. Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications
7. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
8. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
9. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... by one of the nation’s premier cannabis technology and application experts, Chip Baker. ... CEO of Cultivate Colorado. Over the past 30 years, Chip Baker other industry ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... BELLINGHAM, Washington, USA (PRWEB) , ... December 02, ... ... the role of innovative U.S.-owned and -operated small businesses in federally funded research ... SPIE, the international society for optics and photonics . , As part ...
Breaking Biology Technology:
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory Inc ... and security for consumer electronics, and VeriTran ... and retail industry, today announced a global partnership ... way to authenticate users of mobile banking and ... TrulySecure™ software which requires no specialized biometric ...
Breaking Biology News(10 mins):